On Wednesday, Swiss pharmaceutical company Roche said a late-stage study involving non-Hodgkin’s lymphoma patients showed they lived longer without the disease declining when treated with its Gazyva drug, giving a boost to its line-up of cancer treatments.
The news was welcomed by investors, with Roche shares rising by 2.7 percent by 1057 GMT, outpacing the European healthcare sector index which was up 0.7 percent.
Ultimate Gainer Of Healthcare Sector: Esperion Therapeutics Inc (NASDAQ:ESPR) gained 15.16%, and closed at $51.78, during the last trading session, holding market capitalization of $799.64M. $1,743,668 shares changed hands as compared to average volume of $331,860.
Esperion Therapeutics (ESPR), a clinical stage biopharmaceutical organization, focuses on the research, development, and commercialization of oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.
Details about some of the other gainers from healthcare sector are described underneath:
Theravance Inc (NASDAQ:THRX) enhanced 11.89 %, and closed at $11.95, during the last trading session, holding market capitalization of $1.38B. The company has 52-week range of $10.58 - 32.89, and intraday range is $10.64 - 12.04.
Theravance Inc (NASDAQ:THRX) a royalty administration organization, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement with Glaxo Group Limited (GSK).
Pfizer Inc.(NYSE:PFE) raised 1.17 %, and closed at $32.02, soon after Pfizer declared a grant to the Union for International Cancer Control (UICC) for a first-of-its-kind initiative to address the unique challenges facing metastatic breast cancer (MBC) patients. While great progress has been made in the administration of breast cancer, it remains an important and growing global health issue and patients are commonly diagnosed in the advanced stages of the disease.1,2 The Seeding Progress and Resources for the Cancer Community (SPARC): Metastatic Breast Cancer Challenge will provide grants to support proposals worldwide that encourage sustainable change in addressing the specific needs of people living with metastatic breast cancer.
Pfizer Inc.(NYSE:PFE) discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products.
Gilead Sciences, Inc (NASDAQ:GILD) rose 0.93 %, and closed at $107.18, as a biopharmaceutical company, declared that the company’s Board of Directors has authorized a dividend program under which the corporation intends to pay quarterly dividends of $0.43 per share, beginning in the second quarter of 2015, subject to quarterly announcements by the Board of Directors.
Gilead Sciences, (GILD) a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific.
Johnson & Johnson (NYSE:JNJ) soared 1.62 %, and closed at $102.46, during the last trading session, after the news that the company on Tuesday said the U.S. Food and Drug Administration granted priority review for the company’s experimental sarcoma treatment, potentially speeding approval of the drug by up to four months.
Johnson & Johnson (JNJ) together with its subsidiaries is involved in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics.
